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BIRDSHOT RETINOCHOROIDITIS:
THE ORIGINS OF THE DISEASE NAME
Birdshot retinochoroiditis (BRC) is a uveitis
predominantly affecting the posterior
segment of the eye with dual, independent
retinal and choroidal inﬂammation and
almost only seen in Caucasians.1 2 Ryan and
Maumenee ﬁrst described the bilateral reti-
nochoroidal inﬂammatory disease in early
1980, reporting on 13 patients.2 These
authors called it ‘birdshot retinochoroidopa-
thy’ because they found that lesions had a
pattern comparable to that seen in wounds
produced by birdshot shotguns. Later in
1980, Kaplan and Aaberg published a series
of four similar cases ‘involving a choroidal
and retinal pigment epithelium disease not
previously described’, which they also called
birdshot retinochoroidopathy.3 In 1981,
Gass described 11 similar cases and called
the disease vitiliginous chorioretinitis.4
In these ﬁrst articles on the disease,
clinicians had no choice but to rely on
fundus examination and ﬂuorescein angi-
ography (FA). Therefore, the striking
choroidal involvement seen on fundus
examination was at the origin of the
eponym the authors chose to give to the
disease, because both ‘birdshot’ and ‘vitili-
ginous’ refer to the typical rice-shaped,
depigmented choroidal birdshot fundus
lesions (BFLs) that strongly and speciﬁc-
ally characterised the condition. Of the
two designations, ‘birdshot’ became the
universally used and accepted term. It is
understandable that such remarkable chor-
oidal signs determined the naming of the
disease because the retinal and FA signs
were so much less speciﬁc and pathogno-
monic. Nevertheless, an important FA
sign was noted by Gass, who observed
retinal vasculitis of small and large vessels
and the profuse leakage of ﬂuorescein
into the retina in the early disease, as well
as a reduced presence of ﬂuorescein in the
large veins.4 He interpreted this feature as
a substantial delay in retinal arteriovenous
circulation, an explanation that was later
shown to be inexact, thanks to the use of
dual FA/indocyanine green angiography
(ICGA) (see below).5 Retinal involvement
was accounted for by calling the disease a
retinochoroiditis or a chorioretinitis.
Often the disease was also called a retino-
choroidopathy or a chorioretinopathy,
which was inadequate because it is clearly
inﬂammatory, so that the sufﬁx ‘-itis’
should have been used.
THE IMPORTANCE OF HLA-A29
HISTOCOMPATIBILITY ANTIGEN AS A
DISEASE-DEFINING CRITERION
Association of BRC with the HLA-A29
major tissue histocompatibility (MHC)
antigen was ﬁrst reported in 1982, 2 years
after the entity was originally described.6
The association rate was estimated to be
approximately 95% in subsequent
reports.7 8 LeHoang et al9 found that
BRC was associated with the HLA-A29-2
subtype, with a subsequent study conﬁrm-
ing this link as well as an association with
the HLA-A29-1 subtype.10 The HLA-A29
MHC antigen is present in around 7% of
Caucasian populations.11 It is increasingly
Figure 1 Birdshot fundus lesions (BFLs) do not correspond to hypoﬂuorescent dark dots (HDDs).
Case of birdshot retinochoroiditis that lasted for >5 years before the patient agreed to treatment.
Top left: untreated patient; many BFLs are present in the fundus. Bottom left, indocyanine green
angiography (ICGA) frame, the presence of numerous HDDs indicating active disease; however,
there are more angiographically silent BFLs than HDDs. Top right: the fundus after 7 years of
treatment with persisting BFLs. Bottom right: ICGA frame showing that neither resolved HDDs nor
BFLs appear on ICGA (angiographically silent).
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likely that the association is closer to
100% rather than >95% because false
negatives were not so rare when the anti-
body testing method was used.12 The rate
of false-negative results could be reduced
with PCR-based testing.12 The disease has
no known extraocular inﬂammation sites
and yet features the strongest known HLA
association with an MHC antigen with a
greatly increased OR of 157.5 for the
disease when the HLA-A29.02 allele is
present.13 Truly HLA-A29-negative bird-
shot patients are a rarity if they exist at
all, and restricting the diagnosis to
PCR-positive HLA-A29 patients would
exclude a very tiny proportion of cases, if
any. Therefore, the presence of HLA-A29
antigen should be considered an essential
criterion for diagnosing BRC.
ICGA IS ESSENTIAL IN DETECTING
OCCULT CHOROIDITIS AND PERFORM
EARLY DIAGNOSIS
Together with HLA testing, the second
most important element that has drastically
changed the appraisal of BRC was the fact
that ICGA became available to image the
choroid. ICGA ﬁrst came into clinical use in
the early 1990s and enabled insight into
choroidal inﬂammation.14 One substantial
advantage of this method was that it made
possible the detection of occult choroidal
lesions that were inaccessible using
other investigational methods.15 16 ICGA
allowed clinicians to subdivide choroidal
inﬂammation into choriocapillaritis entities
(eg, acute posterior multifocal placoid
pigment epitheliopathy or idiopathic multi-
focal choroiditis) and stromal choroiditis
(eg, Vogt-Koyanagi-Harada (VKH) disease
and BRC).17 18
ICGA ﬁndings in BRC were standardised
in 1999.19 Relevant ICGA signs for diagno-
sis and disease monitoring are the presence
of hypoﬂuorescent dark dots (HDDs) and
fuzziness of large choroidal vessels. HDDs
were suspected to arise from space-
occupying stromal inﬂammatory foci, a
hypothesis that Gaudio et al20 conﬁrmed
histopathologically. Many HDDs in BRC
become isoﬂuorescent on late angiographic
frames, which indicates that (unlike in
VKH) lesions do not occupy the full thick-
ness of the choroidal stroma and do not
involve the inner choroid.21 Fuzziness of
choroidal vessels indicates vasculitis of large
choroidal vessels.14
In several reports, HDDs were thought
and reported to be the angiographic
expression of BFLs.22 They are not,
however, because we now know that BFLs
are silent on ICGA and correspond to
inactive depigmented cicatricial areas
where pigment has been destroyed by the
inﬂammatory mechanism. BFLs can
coexist with HDDs, meaning that the
disease has been present for some time
and is still active (ﬁgure 1). On the other
hand, HDDs may be absent in the pres-
ence of BFLs, meaning that the disease is
no longer active and that what we see are
simply areas devoid of melanocytes,
marking regions of previously active
stromal choroiditis (ﬁgure 1).
Figure 2 (A) Case of birdshot retinochoroiditis diagnosed before birdshot fundus lesions (BFLs) were visible. Top: fundus pictures of the right and
left eye. No BFLs seen. Middle: indocyanine green angiography (ICGA) showing numerous HDDs on both sides. Bottom: diffuse retinal vasculitis
involving veins of all sizes with diffuse leakage. (B) Same case as (A) after 10 years of immunosuppressive therapy. Top: fundus pictures of right and
left eye showing absence of typical BFLs. Middle: ICGA shows a totally normal choroid indicating that the choroid is responding easily to
immunosuppressive therapy with resolution of all lesions. Bottom: ﬂuorescein angiography (FA) shows that retinal vasculitis is substantially
improved; however, discreet leakage is still present, and there is bilateral disc hyperﬂuorescence.
Box 1 Global diagnostic criteria for birdshot retinochoroiditis (BRC)/HLA-A29
uveitis
1. Presence of vitritis in one or both eyes (required)
2. Presence of retinal vasculitis in one or both eyes (required)
3. Stromal choroiditis, as evidenced by ICGA, in both eyes (required)
4. HLA-A29 antigen positivity (required)
5. Visual ﬁeld anomalies in one or both eyes (supportive)
6. Absence of extraocular inﬂammatory site (supportive)
7. Presence of rice-shaped depigmented ‘birdshot lesions’ (BRC fundus lesions)
(strongly supportive but not required)
BRC, birdshot retinochoroiditis; ICGA, indocyanine green angiography.
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HDDs resolved in treatment-naïve
patients with BRC having BFLs without
affecting substantially their size or
number,23 precisely because BFLs corres-
pond to areas of depigmentation that no
longer have any active inﬂammation once
the stromal pigment islets have been
‘digested’. This explains why BRC fundus
lesions are angiographically silent. The
Figure 3 Case of birdshot retinochoroiditis without birdshot fundus lesions at presentation. The patient was referred for retinal vasculitis and also
complained of ﬂoaters bilaterally. Posterior segment showed numerous vitreous opacities but no fundus lesions (top). Middle: diffuse retinal
vasculitis in both eyes. Bottom: typical indocyanine green angiography signs of stromal choroiditis with numerous HDDs and non-recognizable
pattern of choroidal vessels. The patient was immediately tested for the presence of HLA-A29 antigen, which was indeed positive.
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third scenario that can arise consists of
HDDs without BFLs, indicating early
disease before cicatricial depigmentation
has occurred (see below) (ﬁgure 2).
ICGA also demonstrated that choroidal
and retinal inﬂammation develop inde-
pendently, showing that areas of retinal
capillary leakage seen on FA do not cor-
respond to HDDs.24 Dual FA/ICGA
makes it clear that choroidal inﬂammation
promptly responds to therapy, whereas
retinal inﬂammation is more resistant and
is responsible for most of the symptoms
and morbidity caused by the disease.25
ICGA also made it possible to explain
the apparent perfusion delay of retinal
veins reported by Gass, which in fact is a
‘pseudo-delay’ caused by massive extru-
sion of ﬂuorescein into the retina, while
ICGA retinal arteriovenous circulation
time is normal.5
ICGA, CRUCIAL FOR EARLY
DIAGNOSIS/EARLY TREATMENT,
MODIFIED THE PHENOTYPE OF BRC
By far the most important impact of
ICGA in BRC was that choroidal involve-
ment can be detected before the typical
choroidal birdshot lesions are seen on
funduscopy (ﬁgure 2).26 Moreover,
among patients treated before the devel-
opment of BFLs, the appearance of such
lesions could be prevented altogether in
ﬁve of six cases treated within a mean of
6.5 months of the onset of symptoms. In
addition, such lesions were not observed
during a mean follow-up period of
10 years under treatment, implying a
change in the phenotype of BRC (ﬁgure
2).23 In this regard, BRC behaved like
VKH, another stromal choroiditis in
which early, aggressive and prolonged
treatment can prevent the development of
sunset glow fundus.27 The preponderant
role of ICGA in BRC has been reported
by several groups in Europe and recently
also in the USA.19 28–30 Indeed, preven-
tion of BRC fundus lesions requires early
diagnosis, which is not possible with the
present diagnostic criteria.
THE NEED FOR APPROPRIATE
DIAGNOSTIC CRITERIA OF BRC
In 2006, a group of experts published
research criteria for the diagnosis of BRC.31
However, these criteria fail to truly charac-
terise BRC, especially early stage disease.
The major shortcomings are the omission
of ICGA signs, which are present in 100%
of cases19 23; the lack of any reference to
the visual ﬁeld changes that are present in
almost 100% of cases at presentation,
depending on the onset of symptoms32 33;
the characterisation of HLA-A29 antigen as
a merely supporting factor, even though it
is present in almost 100% of cases when
PCR testing is used and the lack of
acknowledgement that keratic precipitates
cannot be an exclusion criterion because
they are present in 15.8%–23% of
treatment-naïve patients.2 4 34 In our series,
the 3/19 (15.8%) patients with keratic pre-
cipitates had been evolving for more than
3 years without treatment.34
There is an urgent need for new and
proper diagnostic criteria for the appro-
priate appraisal and management of BRC,
especially for early disease. In our studies,
we used the following criteria for the
diagnosis of BRC: (1) presence of vitritis
and retinal vasculitis in one or both eyes,
(2) visual ﬁeld anomalies in one or both
eyes, (3) stromal choroiditis as evidenced
by ICGA in both eyes (required),
HLA-A29 antigen positivity (required)
and absence of extraocular inﬂammation
sites. An additional (but not any more
requested) strongly suggestive criterion is
the presence of BFLs. Such criteria are to
be recommended for use in clinical prac-
tice as they correspond to the reality of
the disease presentation (box 1).
HLA-A29 UVEITIS, A MORE
APPROPRIATE NAME FOR BRC?
In case of fulﬁlment of the above-listed
clinical and investigational (especially
angiographic) characteristics, birdshot
cases can be expected to be associated
with HLA-A29 positivity almost 100% of
the time as long as PCR methodology is
used; this rate is by far the highest known
HLA association with a disease.
Furthermore, if the diagnostic criteria
cited here are used together with
HLA-A29 determination, early diagnosis
before the pathognomonic BFLs are seen,
becomes possible. It would therefore be
justiﬁed and even advisable to rename the
disease after the most frequent character-
istic element associated with it, the
HLA-A29 antigen, which must be elevated
to a disease-deﬁning criterion. Indeed, in
the early stage of disease, birdshot lesions
are not disease deﬁning, and classically
relying on their presence leads to diagnos-
tic delay when early diagnosis and treat-
ment are so important.35
In practice, cases devoid of fundus
lesions that were referred to us with vitri-
tis and FA signs compatible with BRC
usually were sent with the a diagnosis of
retinal vasculitis (ﬁgure 3). When per-
forming ICGA, which is absolutely neces-
sary with such a constellation, the
presence of bilateral ICGA angiographic
signs including HDDs and fuzziness of
vessels invariably led to HLA testing.
HLA-A29 positivity conﬁrmed the diag-
nosis in the absence of any BFLs, making
HLA-A29 antigen rather than BFLs the
hallmark of the disease.
PERSPECTIVE AND CONCLUDING
REMARKS
BRC has been characterised by a strong
clinical phenotype since its initial descrip-
tion. Subsequently, additional and even
stronger investigational disease-deﬁning
criteria have become available. HLA-A29
histocompatibility antigen was ﬁrst esti-
mated to be present in up to 95% of BRC
cases, but was ﬁnally found to be present
in almost 100% of cases when PCR meth-
odology was used.12 Long-neglected
ICGA showed a stromal choroiditis in
100% of cases. Together, these two strong
disease-deﬁning criteria have opened the
way to early diagnosis of the disease, no
longer requiring the presence of BFLs,
representing a diagnostic delay until BFLs
appear. Recent data have even shown that
in case of early and sustained treatment,
birdshot lesions are prevented altogether,
changing the phenotype of BRC.23 In this
context of a disease without BFL, the
traditional name no longer corresponds to
the new reality of this clinical entity. To
retain it could even have a deleterious
effect on disease management by delaying
therapeutic intervention during the wait
for birdshot lesions to arise. ‘HLA-A29
uveitis’ more adequately reﬂects the
current, updated clinical context. This
name change would have the same
implications as HLA-B27 uveitis because
both terms reference diseases for
which the etiopathogenicity is unknown
but the exact course of the disease is
well-established.
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